The focus of NSCLC treatment shifted significantly with availability of inhibitors of targetable driver kinases such as mutated epidermal growth factor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements, among others [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.